期刊文献+

SELDI-TOF-MS技术在弥漫性大B细胞淋巴瘤诊断中的意义 被引量:2

Application of SELDI-TOF-MS technique and its significance in diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的应用表面增强激光解析电离飞行时间质谱(SELDI-TOF-MS)技术从弥漫性大B细胞淋巴瘤(DLBCL)石蜡标本中筛选差异蛋白,并检测生发中心型(GCB型)与非生发中心型(non-GCB型)弥漫性大B细胞淋巴瘤之间的差异蛋白。方法运用免疫组化方法检测41例DLBCL中CD3、CD20、CD10、bcl-6和MUM-1的表达,依据Hans分类方法将DLBCL分为预后有显著差异的两种亚型:GCB型和non-GCB型。选用WCX2芯片及SELDI-TOF-MS技术对这两组亚型的石蜡标本进行蛋白指纹图谱检测并比较其不同。15例淋巴结反应性增生的石蜡组织标本作为对照。用Biomarker Wizard软件对数据进行分析。结果在质荷比位于2~20kDa的范围内,以波峰的信噪比(S/N)>5为标准,经软件分析发现DLBCL与淋巴结反应性增生之间共有6个蛋白波峰强度值存在明显差异(P<0.05)。GCB型与non-GCB型DLBCL中共有2个蛋白波峰强度值存在明显差异(P<0.05)。结论免疫组化与SELDI蛋白芯片技术相结合可检测DLBCL患者的特异性标记物,差异蛋白可能有助于DLBCL的诊断。 Objective Surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) technique was employed to detect the protein biomarkers in diffuse large B-cell lymphomas (CLBCLs) from paraffln-embedded tissues. The technique was also used to explore different protein biomarkers between germinal center B-cell hke (GCB) and nongerminal center B-cell like (non-GCB) types of DLBCLs. Methods 41 cases of DLBCLs were selected to do the immunohistochemistry with a panel of antibodies CD3, CD10, CD20, bcl-6 and MUM-1. The DLBCLs were classified into GCB and uon-GCB phenotype according to Hans' algorithm. SELDI technique (WCX2 proteinchips) was used to detect the paraffinembedded tissue of DLBCLs. 15 cases of reactive hyperplasia of lymph node were used as control. The data were analyzed by Biomarker Wizard solftware. Results In the m/z range of 2-20 kDa, as the peak' s S/N 〉 5, 6 different proteins ( 8 584, 8 711, 10 134, 4 287, 2 031, and 2 011 Da) were found between DLBCL and reactive hyperplasia of lymph node ( P 〈 0.05). 2 different proteins (2 153 Da, 3 156 Da) were detected between GCB and nonGCB-DLBCL ( P 〈 0.05). Conclusions The specific biomarkers of DLBCL could be detected by using immunohistochemical method and SELDI proteinehip technology, which might be help in the lymphoma diagnosis and evaluation of the prognosis. The proteins 8 584, 8 711, 10 134, 4 287, 2 031, and 2011 Da might be useful in the diagnosis of DLBCL. The proteins 2 153 Da and 3 156Da might have significance in the classification of DLBCL.
出处 《诊断病理学杂志》 CSCD 2009年第6期409-412,共4页 Chinese Journal of Diagnostic Pathology
基金 山西省自然科学基金资助项目(编号2007011127) 山西省科技攻关项目(编号20080311062-2) 山西省留学人员重点科研资助项目(编号2008-10-5)
关键词 DLBCL 分子亚型 SELDI—TOF—MS 蛋白组学 免疫组化 预后 DLBCL Phenotype SELDI-TOF-MS Proteomics IHC Prognosis
  • 相关文献

参考文献17

  • 1Hunt KE, Reichard KK. Diffuse large B-cell lymphorna [J]. Arch Pathol Lab Med, 2008, 132(1):118- 124. 被引量:1
  • 2Coifller B. Diffuse large cell lymphoma[J] .Curr Opin Oncol,2001, 13(5) :325 - 334. 被引量:1
  • 3Haas CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-eel lymphoma by immunohistochemistry using a tissue mieroarray [J]. Blood, 2004, 103(1):275-282. 被引量:1
  • 4Sjo LD, Poulson CB,Hansen M, et al. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups[J]. Eur J Haematot,2007,79(6) :501 - 507. 被引量:1
  • 5Hutchens WT, Yip Tr. New desorption strategies for the mass spectrometric analysis of macromolecules[J]. Rapid Commun Mass Spectrom, 1993, 7:576-580. 被引量:1
  • 6闵大六,周晓燕,陆洪芬,许越香,范月珍,郑爱华,施达仁.B细胞性非霍奇金淋巴瘤中BCL-6、CD10和BCL-2的蛋白表达及其临床病理意义[J].中国癌症杂志,2006,16(3):169-173. 被引量:9
  • 7Steven H, Campo E, Harris NL, et al.WHO classification of tumors of haematopoiefic and lymphoid tissues[M]. Lyon: IARC Press, 2008.233 - 237. 被引量:1
  • 8Issaq HJ, Conrads TP, Prieto DA, et al. SELDI TOF MS for diagnostic proteomics[J]. Anal Chem, 2003, 75(7) : 148A - 155A. 被引量:1
  • 9Zhu H, Snyder M. Protein chip technology [ J ]. Curr Opin Chem Biol,2003,7( 1 ) :55 - 63. 被引量:1
  • 10Kas K. On the technicalities of discovering and applying protein biomarkers for cancer prevention[J]. Eur J Cancer Prey, 2004, 13(5):437 -446. 被引量:1

二级参考文献21

  • 1Ye BH,Rao RS,Chaganti K,et al.Cloning of BCL-6,the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma[J].Cancer Res,1993,53(12):2732-2735. 被引量:1
  • 2Dent AL,Vasanwala FH,Toney LM.Regulation of gene expression by the proto-oncogene BCL-6[J].Critical Reviews in Oncology/Hematology,2002,41(1):1-9. 被引量:1
  • 3Zhang A,Ohshima K,Sato K,et al.Prognostic clinicopathologic factors,including immunologic expression in diffuse large B-cell lymphomas[J].Pathol Int,1999,49(12):1043-1052. 被引量:1
  • 4Jaffe ES,Harris NL.Stein H,et al,eds.:Pathology and Genetics of Tumours of Haematopoitetic and Lymphoid Tissues[M].Lyon,France:IARC Press,2001,119-189. 被引量:1
  • 5Ponzoni M,Ferreri AJ,Pruneri G,et al.Prognostic value of BCL-6,CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas:identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome[J].Int J Cancer,2003,106(2):288-291. 被引量:1
  • 6Dogan A,Bagdi E,Munson P,et al.CD10 and BCL-6 expression in paraffin section of normal lymphoid tissue and B-cell lymphomas[J].Am J Surg Pathol,2000,24(6):846-852. 被引量:1
  • 7Kraus MD,Haley J.Lymphocyte predominance Hodgkin's disease,the use of BCL-6 and CD57 in diagnosis and differential diagnosis[J].The Am J Sur Pathol,2000,24(8):1068-1078. 被引量:1
  • 8Alizadeh AA,Eisen MB,Davis RE,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J].Nature,2000,403(6769):503-511. 被引量:1
  • 9Ree HJ,Yang WI,Kim CW,et al.Coexpression of BCL-6 and CD10 in diffuse large B-cell lymphomas:significance of BCL-6 expression patterns in identifying germinal center B-cell lymphoma[J].Hum Pathol,2001,32(9):954-962. 被引量:1
  • 10Leval LD,Ferry JA,Falini B,et al.Expression of BCL-6 and CD10 in primary mediastinal large B-cell lymphoma,evidence for derivation from germinal center B cells[J].Am J Surg Pathol,2001,25(10):1277-1282. 被引量:1

共引文献16

同被引文献25

  • 1肖健,王树森,黄岩,陈丽昆,管忠震,黄慧强,夏忠军,徐瑞华,林桐榆.62例鼻型NK/T细胞淋巴瘤的预后因素分析[J].癌症,2006,25(9):1173-1177. 被引量:5
  • 2许洋.蛋白质指纹图谱技术在实验诊断与临床医学中的研究进展[J].基础医学与临床,2007,27(2):134-142. 被引量:36
  • 3Mukesh Vemm,Wright JR,Samir M,el a1.Proteomic approaches with in the NCI early detection research network for the discovery identification of cancer biomarker[J].Ann New York Acad Sci,2001,945(1):103-105. 被引量:1
  • 4Wasinger VC,Cordwell SJ,Cerpa Poljak C,et al.Progress with gene product mapping of the Mol1icutes:Mycopiasma genitalium[J].Electrophoresis,1995,16(7):1090. 被引量:1
  • 5Han JZ,Wang YB.Proteomics:present and future in food science and technology[J].Trends Food Sci Tech,2008,19(1):26-30. 被引量:1
  • 6Li JN,Zhang Z,Rosenzweig J,et al.Proteomics and Bioinformatics Approaches for identification of serum biomarkers to detect breast cancer[J].Clinical Chemistry,2002,48(7):1296-1304. 被引量:1
  • 7Honda K,Hayashida Y,Umaki T,et al.Possible detection of pancreatic cancer by plasma protein profiling[J].Cancer Res,2005,65(22):10613-10622. 被引量:1
  • 8Liang Y,Fang M R,Li JC,et al.Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry[J].Experiment Molecul Patholo,2006,81(2):176-180. 被引量:1
  • 9Pan YZ,Xiao XY,Zhao D,et al.Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry[J].Chin Med,2005,85(45):3172-3178. 被引量:1
  • 10Stranneheim H,Orre LM,Janne Lehti(o) J,et al.A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells[J].Proteome Science,2009,7(1):43. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部